Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidance Outlines Testing Parameters For MRI-Compatible Devices

This article was originally published in The Gray Sheet

Executive Summary

The new document details how companies can test passive medical devices, such as orthopedic implants and stents, against risks from radiofrequency-induced heating during an MRI scan.

You may also be interested in...



Surgeons Warned Of Overheating From NeuroBlate Probes During MRI Use

Podcast: FDA, Med Institute Studying MRI Safety of Passive Devices

FDA has partnered with the Med Institute, part of Cook Group, to spend the next three years trying to understand what standards could be used to determine whether a device is MRI compatible.

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034627

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel